Skip to content

A treatment for the Gallbladder stone with Dietary Advice

An Open-Label Pilot Study to Evaluate the Effectiveness of Vengara Parpam with a Dietary Regimen for The Management of Cholelithiasis (Pithapai Kaal) - NILL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087598
Enrollment
30
Registered
2025-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K802- Calculus of gallbladder without cholecystitis

Interventions

Intervention1: Vengara parpam: 200 300 mg, twice daily, mixed with tender coconut water (Elaneer). 90 days Control Intervention1: NIL: NIL

Sponsors

Dr M Subhathra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with acute or chronic cholecystitis. Gallstone size greater than 5 mm but less than 12 mm. Age group: 20 60 years. All genders Patients willing to participate in the trial. Patients are willing to undergo USG abdomen follow-ups and provide samples for routine investigations.

Exclusion criteria

Exclusion criteria: History of pancreatitis. Presence of gastroesophageal reflux disease (GERD). Patients diagnosed with irritable bowel syndrome (IBS). Cases of septicemia. Patients with jaundice. Diagnosed cases of cholangitis.

Design outcomes

Primary

MeasureTime frame
The therapeutic effectiveness of Vengara Parpam combined with an Dietary Regimen in alleviating the symptoms of cholelithiasis (Pithapai Kaal) will be determined by assessing the reduction in gallstone size and symptom improvement using clinical evaluation and diagnostic imaging.Timepoint: 3 months.(If the size is reduced (or) partially reduced ,the medicine will be repeated).

Secondary

MeasureTime frame
The Therapeutic effectiveness of Vengara Parpam for the management of cholelithiasis (Pithapai Kal) will be determined by Gastrointestinal Quality of Index (GIQLI). To reduce symptoms of cholelithiasis, such as Heaviness of the Abdomen, pain, nausea, and vomiting. Timepoint: 3 months.(If the size is reduced (or) partially reduced ,the medicine will be repeated).

Countries

India

Contacts

Public Contactsubhathra mani M

National Institute of Siddha

christianvijila@gmail.com99625

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026